| AlInost all the living cells inGluding leukemic cells intake ironmoshy through the pathway of transferrin(TD -- transferrinreceptor(Tm). Tm is highly exPressed on erythrocytic cells andrapid-proIiferating ceIls(including leukendc cells).The studies showedthere is soluble fragment of Tm in serm called Serum transferrinreceptor(sTm) which can reflect to a certain degree, the quantities ofTffe on the cells,and is associated with the proliferation of leukemiccells.But untill noW few of the stUdies about sTm in acute'leulemia(AL) were reported and the results were not similar, and there.is still no relative stUdy in our cou-ntryIt was not yet reported about thestUdy of sTffe combining with iron metabolism in AL.AL is one of the malignant boors which severely threatenschildren's life, while anemia is one of the main clinical sitUations, few6nNk% 2002 6Rnt$&ikt fatteA$$}L sTfR. sEPO W&$#&X4UinMX#ffnstUdies conceming the relationships of anemi4 serum erythrpohetinand iron metabolism have been performed.in order to provide the rational for clinical diagnosis, detenninationof theraPeuhcal effect and judgement of prognosis, the relationshipbetween sTm and the proliferative ability ofAL cells was inveshgated- combining with the measurement of serum iron metabolism indexes. including serum fetritin(SF),serurn transferrin(sTD,serum iron(SD,hemoglobin(Hb) and countS of priInary and immature leucocytes ofbone marrow,countS of nucleate erythrocytes of bonemarrowMeanwhile,to further disclose the pathogenesis of anemia ofAL and to provide rational for clinical theraPy,serum etwopoietin(sEPO ) was studied to explore the relationships of anemia,sTm, ironmetabolism and sEPO.Methods 48 children with AL entered the study,including 37patients of acute lymphocytic leukemia(ALL)(30 patients of Ll,7patients of L2);24 of 37 patientS untreated before hospitalization(beforetheraPy group), l4 of 24 patients Who got remission of bone marrow in. the end of the 4th week after chemotheraPy(4-week group),l0 of l4. patients who maintained remission of bone marrow and were measuredat the end of the 8th week(8-week group),13 of 37 patientS Who gotcomplete remission from 6 months to 3 years(long-term grouP).1lpatients of acute myelocytic leukemia(na)(4 patentS of Ml,7patients of M2)fnone of these pahentS treated before'7N}8X$20()2 WA1$all&Z 2ttefa$$)L sTfR. sEro fo&#ffi&X5UnMX'WnhospitalisatiOn(before theraPy grouP),5 of ll patients Who gOtremission of bone marrow in the end of the 4th week afterchemotheraPy(4-week group), 5 of 5 who maintained remission ofbone marrow and were measured at the end of the 8th week(8-weekgrouP).Meanwhile,20 age-matChed healthy children were selected ascolltrOl grouP. -4Inl of venous blood was taken frOm each chiId in the early.moming befOre eating any foods, the sean samPle was collected aftercentrifugation and stored at -70oC. sTm was measured by sandwichELISA,sEPO was measured by Radiotwunoassayand SF sTf,SI waSmeasured by Chemiluminescence AssayTUrbidAnetry and FlarneAssayrespectivelyResults(l) sTffe 1evel of before theraPy group of ALL was 24.73il2.38nmol&, M was 27.09i l9.37nmomi,and cofltrol group was30.49f9.78nmoffo.Both ALL and M were no difference with thatof control grOuP(P>0.05), 4-week grouP of ALL was 55.41 i22.0lnmoMi,M was 50.7l l20.99nmol/L.Both were significantly'higher than that of before theraPy group and healthy grouP(P<0.0l),'8-week group of ALL was 33.07l 16.l1nmol/L,AML was 30.99il2.90nmol/L, Both decreased to normal level (P>0.05), long-termgroup of ALL was 33.07 l l6. l lnmol/L, Which was no differnce withthat of control group(P>0.05). There is no difference betWeen ALL and8nNX$2002 ffA4$kitZ 3#An$t)L sTrs. sEP() fo#$kAX$knMX#ffAM in all the grouPs.(2) SF level of befOre theraPy group of ALL was 395.63il97.53ng/ml, AML was 588.73 i287.54ng/ml, control group was40.73l l9.90ng/ml.Both ALL and...
|
PDF Full Text Request